The conventional recommendation is to inject BPC-157 close to the injury site. The reasoning sounds intuitive: higher local concentration before the peptide distributes. But the research that established BPC-157's healing effects doesn't clearly support this recommendation — and looking at how those studies were actually run is instructive.
What the foundational studies used
The foundational BPC-157 tendon and injury-healing research — including work from Sikiric's lab, which produced the vast majority of published studies in this area — used injection directly into the abdominal cavity. Not near the injury. Not intramuscular. Into the peritoneal cavity: the most systemic delivery method available.
A 2025 systematic review in HSS Journal examined 36 studies from 1993 to 2024. The near-universal methodology was systemic injection, not localized delivery near the site of damage. Healing benefits were still observed. Fibroblast migration. Tendon outgrowth. Improved biomechanics at the injury location.
Sikiric's own nerve-healing work found comparable results across three delivery methods: injection into the abdominal cavity, oral administration, and local application at the anastomosis site. The peptide appears route-flexible.
The mechanism explains why
BPC-157 does not work like a topical anti-inflammatory. Its effects run through systemic signaling pathways. When BPC-157 circulates, it activates FAK-paxillin pathways that drive fibroblast migration to the injury site. It modulates the nitric oxide system. It upregulates VEGF and promotes angiogenesis.
These cascades are triggered by the peptide circulating systemically — not by local deposition. Once absorbed from any injection point, BPC-157 reaches the injury site through blood flow. Injured tissue is already preferentially vascular (inflammation increases local blood flow), which may enhance delivery there regardless of where the injection occurred.
What the research doesn't contain
There is no published human trial comparing abdomen injection with shoulder injection for shoulder tendinitis and measuring which produces better functional outcomes.
The near-site recommendation is clinical convention, not a finding from controlled head-to-head data. It's a plausible extrapolation from pharmacokinetic reasoning, but not an empirically established superiority.
What does have evidence behind it
Consistent daily dosing. BPC-157 has a short half-life. Daily injection maintains circulating levels. That consistency — not the injection location — is the variable with the strongest support in the published research.
If you've been second-guessing your injection site, the data doesn't give you a strong reason to.
PPL covers research peptides for informational purposes only. Nothing here is medical advice. BPC-157 is not approved for human use by any regulatory agency and is sold for research purposes only.